



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Gontivimab

Cat. No.:	HY-P99647
CAS No.:	1257358-38-5
Target:	RSV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Gontivimab (ALX-0171; VR-465) is a potent anti-RSV prefusion F protein nanobody with a K_D value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung ^[1] .	
IC₅₀ & Target	K_D : 0.113 nM (RSV prefusion F protein) ^[1]	
In Vitro	Gontivimab (0-100000 nM) shows antiviral activity with IC ₅₀ s of 0.1, 0.4 nM for RSV-A, RSV-B 18537 strain, respectively ^[1] . Gontivimab binds to antigenic site II of F protein ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Gontivimab (1-68 mg/kg; intranasal administration or nebulization) reduces the RSV load in the nose and lungs in rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Rats (RSV Tracy) ^[1]
	Dosage:	1-68 mg/kg
	Administration:	Intranasal administration or nebulization; once (day 2 or day 3) or twice (day 2 and day 3)
	Result:	Resulted in significant viral load reductions in the lungs ranging.

REFERENCES

[1]. Detalle L, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2015 Oct 5;60(1):6-13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA